Hold CL at modest Underweight sizing (≤2% portfolio) with $84.00 hard stop and $84.30 volume override
Hold CL at modest Underweight sizing (≤2% portfolio, below benchmark weight) with hard stop at $84.00 plus $84.30 close-on-volume override. The 9/24 binding lesson governs: default to Hold rather than trim when bearish signal stack meets intact franchise fundamentals. Reject Aggressive Analyst's coiled-spring framing (unconfirmed direction, 1:1.4 R/R not asymmetric), reject Conservative Analyst's $84.50 stop tightening (whipsaw-prone 25 cents above Oct 2 low), reject trim trigger at $87.50 (execution risk below 200 SMA at $87.87). Volatility compression setup is real but directionally unconfirmed. Patience with deadline is correct stance; 2.46% dividend yield provides carry during wait. Staged re-engagement only on confirmed technical reversal; trim ONLY into $87.87-$89.54 resistance band.
| Position | Action |
|---|---|
| If currently above modest Underweight threshold (≤2% of portfolio) | Trim toward modest Underweight; magnitude cap 5-7% of position to reach ~93-95% of benchmark |
| If at or below modest Underweight threshold | No new sizing action required |
| Trim proceeds re-deployment | 60% into T-bills at ~5% risk-free, 40% as dry powder for $82-84 re-entry if capitulation flush |
| Capitulation zone (confirmed close below $82.00 on volume) | Prepare for $80-82 structural floor defense |
Colgate-Palmolive is a cash-generating compounder experiencing a textbook accumulation opportunity where technical compression, improving fundamentals, and late-cycle defensive rotation create a 3.2:1 reward-to-risk trade at $86.19.
| Indicator | Value | Signal |
|---|---|---|
| close_200_sma | 87.87 | bearish |
| close_50_sma | 89.54 | bearish |
| close_10_ema | 85.82 | bullish |
| rsi | 44.59 | neutral |
| macd | -1.22 | bearish |
| macd_histogram | -0.004 | neutral |
| bollinger_middle_band | 86.61 | neutral |
| atr | 1.51 | neutral |
Support: 84.3 · 85.82 | Resistance: 86.61 · 87.87 · 88.92 · 89.54
Technical analysis indicates CL remains in a medium-term downtrend with price below key moving averages, though near-term momentum is stabilizing. The 50 SMA is declining and rolling over toward the rising 200 SMA, raising death cross risk. RSI recovery from oversold and MACD histogram compression toward zero suggest bearish momentum may be exhausting. ATR contraction to 1.51 signals a volatility squeeze that typically precedes directional expansion. Recommendation: HOLD with bullish bias—await confirmed breakout above $87.87 (200 SMA) before establishing long positions, with stop at $84.30 (Bollinger lower band).
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Confirmed close >$89.54 (50 SMA) with positive MACD histogram
Then: Second tranche 33%; upgrade to Overweight at 80% benchmark
Margin structure and cash flow prove durable pricing power
↩ rebuts: “Bear ignores structural margin strength; CL passed mid-single-digit price increases in 2022-2024 without volume collapse”
EV: +13.7% to $98 (12-18 month target)
CL is mispriced as a defensive compounder when it's actually a deteriorating momentum stock in a hostile macro regime; the bull confuses a defensive name with a defensive stock and the 6-7% shareholder yield is a long-term metric that doesn't protect against near-term losses.
· concedes: CL pays a reliable 2.43% dividend while waiting for clarity; Beta of 0.32 means downside is structurally limited in absolute terms; Long-term holders aren't getting killed; CL is shareholder-aligned with consistent capital return
→ vs conservative: The conservative analyst is wrong on risk calculus — death cross at rising 200 SMA support is a tradable bottom, not a breakdown signal; 21.28x forward P/E is justified by 6-7% shareholder yield and 0.32 beta in higher-for-longer regime where low-beta defensive cash flows should command premium, not discount
→ vs neutral: The neutral analyst is missing the asymmetric payoff — waiting for 'clarity' means chasing after the move happens; volatility compression into Q3 earnings catalyst is positioning, not abandonment; HOLD is the aggressive play, not passive
Market Cap
$69.52B
P/E Ratio (TTM)
34.33
Forward P/E
21.28
PEG Ratio
1.59
Price to Book
294.63
EPS (TTM)
$2.54
Forward EPS
$4.10
Dividend Yield
2.43%
Beta
0.322
52-Week High
$99.33
52-Week Low
$74.55
50-Day Avg Price
$89.45
200-Day Avg Price
$88.55
Revenue (TTM)
$21.05B
Gross Profit
$12.72B
EBITDA
$4.98B
Net Income (TTM)
$2.04B
Gross Margin
~60.4%
Operating Margin
20.97%
Profit Margin
9.68%
Return on Equity (ROE)
267.37%
Return on Assets (ROA)
15.84%
Total Assets
$16,790M
Total Liabilities
$16,224M
Stockholders' Equity
$236M
Treasury Stock
$28,931M
Cash & Equivalents
$1,370M
Long-Term Debt
$7,823M
Short-Term Debt
$34M
Total Debt
$7,857M
Net Debt
$6,487M
Goodwill + Intangibles
$4,595M
Working Capital
$160M
Net Tangible Assets
-$4,359M
Current Ratio
1.026
Operating Cash Flow (TTM)
~$5.34B
Free Cash Flow (TTM)
$3.46B
Q2 2026 Operating Cash Flow
$995M
Q2 2026 Free Cash Flow
$867M
Q2 2026 CapEx
-$128M
Diluted Shares Outstanding
802M
Combined Shareholder Yield
~6-7%
Debt/Equity Ratio
1,388x
Strengths
Concerns
Colgate-Palmolive is a high-quality defensive blue-chip consumer staples company with a notably low beta of 0.322 and strong brand portfolio generating approximately 60% gross margins. The company produces robust free cash flow of $3.46B annually, which fully supports a combined dividend and buyback program yielding 6-7%, while net debt has declined from $7.54B to $6.49B over the past year. Key risks include elevated TTM valuation metrics distorted by a Q4 2025 one-time charge, high leverage relative to minimal equity, and slow top-line growth in a competitive environment.
Macro: Hawkish macro regime with 10-year Treasury at highest since 2002 and 96% probability of zero 2026 Fed cuts (Polymarket, $8.8M volume). Sticky inflation not re-accelerating (12% odds of >4.5% CPI in 2026). Labor market slowing but not breaking (September miss). Recession odds low at 6%. Tech at all-time highs (NVDA, AMD); consumer discretionary being 'pummeled' by higher rates. Strong USD signaled by gold weakness; Iran conflict driving shipping/import cost inflation. No company-specific news for CL; quiet pre-Q3 earnings (late October). CL fairly valued at ~22-25x forward P/E with ~3% long-term growth.